Showing 6411-6420 of 10731 results for "".
Long-term efficacy and safety data from ILUMYA™ clinical trials
https://practicaldermatology.com/topics/psoriasis/long-term-efficacy-and-safety-data-from-ilumya-clinical-trials/19858/Explore efficacy and safety data for ILUMYA™ from the reSURFACE 1 and reSURFACE 2 Phase 3 trials and extension studies.COVID-19 Coping Strategies
https://practicaldermatology.com/topics/practice-management/covid-19-coping-strategies/19755/Nina Chaifetz, LCSW-R, a licensed clinical social worker and co-founder of Lotus Psychotherapy in New York, offers strategies to use every day to lessen anxiety, especially now as the COVID-19 pandemic continues to disrupt our world and increases feelings of fear, stress, and uncertainty.Advances in Skin Cancer Detection
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advances-in-skin-cancer-detection/19685/Early detection is the best defense against skin cancers, and new technologies are assisting in the fight, says Anthony Rossi, MD. He highlights new and emerging advancements.Elastin - The underappreciated skin fundamental
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/elastin-the-underappreciated-skin-fundamental/19672/Join Macrene Alexiades, MD, PhD, FAAD as she discusses elastin and its role as a critical, yet often underappreciated, skin fundamental. In this webinar, she explains why lack of elastin is the root cause of skin laxity and what happens when there is a cessation of elastin synthesis. Dr. Alexiades rDermWireTV: AbbVie to Acquire Allergan, Duobrii Launches, SDPA at 25
https://practicaldermatology.com/topics/psoriasis/dermwiretv-abbvie-to-acquire-allergan-duobrii-launches-sdpa-at-25/19629/In a deal with an equity value of approximately $63 billion, AbbVie has agreed to acquire Allergan. The new company is positioned for new growth platforms and a diversified revenue base; the deal will be immediately accretive to earnings per share, AbbVie says. The Society of Dermatology Physician AThe Skin Cancer Foundation at 40
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-skin-cancer-foundation-at-40/19614/Skin Cancer Foundation president Deborah Sarnoff, MD talks about the Foundation's accomplishments, its current focus, and future goals. Founded in 1979, the foundation has helped educate the public on skin cancer risk and supports dermatologists in practice.Skin of Color Society in NYC; Highlights from 2017
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-skin-of-color-society-in-nyc-highlights-from-2017/18359/In this special edition of DermWireTV, Seemal Desai, MD offers a recap of the Skin of Color Society's media day in New York. Plus, a look at the most-read and viewed content from Practical Dermatology® magazine and DermTube.com, featuring Heidi Waldorf, MD, Linda Stein-Gold, MD, Ted Rosen, MD, JoelSunscreen Ratings, Long Live Skin Launches, SCALE Highlights
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-sunscreen-ratings-long-live-skin-launches-scale-highlights/18471/Consumer Reports says that one-third of sunscreens tested in its latest evaluation provided less than half of the SPF protection touted on the label. For its part, the American Academy of Dermatology is reminding patients that sunscreen ingredients are safe. The Environmental Working Group continuesBehind the Scenes: Preparing to Inject
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/aad-orlando-daily-coverage-day---wvpotpwa/18529/Live injection sessions are a great way to learn techniques and review injection anatomy for best outcomes and patient safety. Doris Day, MD speaks about these issues and shares her perspective on preparing to inject for these sessions.Biosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO Brent